Active Research Studies: Prostate Cancer

Comprehensive Cancer Centers runs Phase II and Phase III research studies for prostate cancer:

A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency **ATM COHORT IS CLOSED**
Study#: i2422 Phase: III
Contact Us: For information about this clinical study, Email Us, or use our form field.

DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium‐223 for Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Study#: i2626 Phase: III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM) **OPEN TO PART 2**
Study#: 18128 Phase: II
Contact Us: For information about this clinical study, Email Us, or use our form field.

An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either Abiraterone or Enzalutamide
Study#: i2682 Phase: II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
Study#: i2666 Phase: III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer(mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
Study#: i2662 Phase: III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Study#: i2660 Phase: III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer **COHORT 1 OPEN; COHORT 2 CLOSED TO ENROLLMENT**
Study#: i2681 Phase: III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
Study#: 19135 Phase: II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Study#: i2727 Phase: III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy For Localized Prostate Cancer
Study#: i2779 Phase: II
Contact Us: For information about this clinical study, Email Us, or use our form field.